Mark Frye, MD | Mayo Clinic
WHY A TASK GROUP?
Formed in November 2012, the Biomarkers Task Group engages members in identifying biological indicators, along with developing and promoting diagnostic tools. The task group uses the results of current investigations in future directions of research.
- Multiple research projects ongoing
- Multiple publications in draft
- For a description of this task group’s recently completed clinical study, please visit the ClinicalTrials.gov page: “The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression”. This program was generously funded by a gift from a University of Michigan Eisenberg Family Depression Center donor.
- Completion of enrollment, follow-up, and reporting of the BIO-K study
- Lapidos, A., Lopez-Vives, D., Sera, C. E., Ahearn, E., Vest, E., Senic, I., Voort, J. V., Frye, M., Goes, F. S., Achtyes, E., Greden, J., & Parikh, S. V. (2022). Patients’ recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2022.11.090
- Parikh, S. V., Lopez, D., Vande Voort, J. L., Rico, J., Achtyes, E., Coryell, W., Goddard, A., Goes, F., Greden, J. F., Singh, B., Kaplin, A., Frye, M. A., Maixner, D., Watson, B., Drake, K., Tarnal, V., Riva-Posse, P., Bobo, W. V., & Bio-K Study Team. (2021). Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. Psychopharmacology Bulletin, 51(3), 109–124. https://www.ncbi.nlm.nih.gov/pubmed/34421148
For more information about this task group, please contact Program Manager Diana Burnett ([email protected]).
page updated: 02/2023